GLP-1 Drugs Linked to Lower Fracture Risk in People With Type 2 Diabetes
Glucagon-like peptide-1 (GLP-1) receptor agonists may be associated with a lower risk of fragility fracture in patients with type 2 diabetes, a study published in JAMA Network Open found.
We haven't written up this one. JAMA has the full story — the link below goes straight to it.